MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2026-03-31.

Income Overview

Net Income
-$505,606K
EPS
-$2.77
Unit: Thousand (K) dollars

Income Statement
2026-03-31
Research and development
456,660
Acquired in-process research and development
0
General and administrative
76,242
Total operating expenses
532,902
Interest income, net
25,330
Other (income) expense, net
2,181
Loss before provision for income taxes
-505,391
Provision for income taxes
215
Net loss
-505,606
Basic EPS
-2.77
Diluted EPS
-2.77
Basic Average Shares
182,421,233
Diluted Average Shares
182,421,233
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$505,606K Loss beforeprovision for income taxes-$505,391K Provision for income taxes$215K Interest income, net$25,330K Other (income)expense, net$2,181K Total operatingexpenses$532,902K Research and development$456,660K General andadministrative$76,242K

Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT)